Abstract:Osimertinib (AZD9291) is an oral, potent, irreversible EGFR-TKI, selective for both EGFR-sensitizing (EGFRm) and T790M resistance mutations. Following positive outcomes from recent Phase I and II trials, osimertinib is now recommended for patients with EGFR T790M mutation-positive advanced non-small cell lung cancer (aNSCLC). AURA17 (NCT02442349) is an open-label, single arm, Phase II study investigating the efficacy and safety of osimertinib in an Asia-Pacific patient population with EGFRm T790M mutation-positive locally advanced or metastatic NSCLC, who had progressed following EGFR-TKI therapy or EGFR-TKI and chemotherapy. T790M-positive status was confirmed via central testing of biopsy samples using the cobas® EGFR Mutation Test. Inclusion required measureable disease, performance status (PS) 0/1, and acceptable organ function; asymptomatic brain metastases were allowed. Patients received osimertinib 80 mg once daily until disease progression. The primary endpoint was objective response rate (ORR) according to RECIST 1.1 (by blinded independent central review, BICR). Secondary objectives included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival, and safety and tolerability. As of 4 March 2016 data cut-off, 171 patients were enrolled, with 166 evaluable for response: median age, 60.0 years; female, 69%; Asian, 98%; never smokers, 78%; PS 0/1, 15%/85%; EGFR Exon 19 and L858R mutations, 64% and 34% patients, respectively; second-/≥third-line, 32%/68%; median treatment exposure, 5.6 months. Confirmed ORR and DCR (95% CI) by BICR were 60% (52, 68) and 88% (82, 92), respectively. DoR and PFS are not calculable as data is immature. Causally-related adverse events (AEs) grade ≥3 were reported in eight (5%) patients. AEs leading to dose interruption or dose reduction occurred in seven (4%) and two (1%) patients, respectively. Six (4%) patients discontinued treatment due to AEs, two (1%) causally-related AEs as assessed by investigator. The most commonly reported AEs (%, [grade ≥3]) were diarrhoea (29%, [0]), rashes and acnes (grouped terms) (20%, [0]), and dry skin (grouped terms) (17%, [1%]). Interstitial lung disease-like events were reported in three (2%) patients. AURA17 demonstrated clinical efficacy of osimertinib in Asia-Pacific patients with EGFR T790M mutation-positive aNSCLC, with an ORR of 60% and DCR of 88% that are comparable to global Phase II trials. Osimertinib was well tolerated, with a low frequency of AEs grade ≥3. No new safety signals were seen and the pattern of AEs was consistent with global studies

Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Patients with Advanced NSCLC Who Are Harboring EGFR T790M.

MA15.10 Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

<i>EGFR</i> mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

The Impact of EGFR T790M Mutation Status Following the Development of Osimertinib Resistance on the Efficacy of Osimertinib in Non‐small Cell Lung Cancer: A Meta‐analysis

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with an Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

The Status of the EGFR T790M Mutation is Associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

Primary and Acquired EGFR T790M-mutant NSCLC Patients Identified by Routine Mutation Testing Show Different Characteristics but May Both Respond to Osimertinib Treatment

Risk Factors of Acquired T790M Mutation in Patients with Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

A Comprehensive Prognostic Analysis of Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients with Acquired EGFR-T790M Mutation: a Real-World Study

Investigating Novel Resistance Mechanisms to Third Generation EGFR TKI Osimertinib in Non-Small Cell Lung Cancer Patients Using Next Generation Sequencing.

1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Different Characteristics and Survival in Non‐small Cell Lung Cancer Patients with Primary and Acquired EGFR T790M Mutation

Insensitivity to T790M Mutation? A Pooled Analysis of Outcomes Following Osimertinib for the Treatment of NSCLC Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutation

P3.02b-096 Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results

Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC

Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Addition to Complex Mutations Treated with Osimertinib Have a Poor Clinical Outcome: A Real-World Data Analysis.

Low T790m Relative Allele Frequency Indicates Concurrent Resistance Mechanisms And Poor Responsiveness To Osimertinib

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC